AXGN (Axogen) Total Stockholders Equity : $99.4 Mil (As of Sep. 2024)

View and export this data going back to 1986. Start your Free Trial

What is Axogen Total Stockholders Equity?

Axogen's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $99.4 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Axogen's Book Value per Share for the quarter that ended in Sep. 2024 was $2.26. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Axogen's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.69.

Axogen Total Stockholders Equity Historical Data

The historical data trend for Axogen's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axogen Total Stockholders Equity Chart

Axogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

132.15

123.15

112.55

101.00

95.67

Axogen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															97.81	95.67	93.16	95.69	99.41

Axogen (NAS:AXGN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Axogen's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(99.407	-	0)	/	44.0023
	=	2.26

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Axogen's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.856	+	67.006)	/	99.407
	=	0.69

Axogen Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Axogen's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Axogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

0HKD:UK

Address

13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615

Website

https://www.axogeninc.com

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Executives

Angelo Scopelianos	officer: Chief R&D Officer	C/O AXOGEN, INC., 13631 PROGRESS BOULEVARD - SUITE 400, ALACHUA FL 32615
Karen L. Zaderej	director, officer: CEO	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Erick Wayne Devinney	officer: VP, Clinical&Translational Sc	13631 PROGRESS BLVD SUITE 400, ALACHUA FL 32615
Michael Patrick Donovan	officer: VP Operations	C/O AXOGEN, INC., 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL 32615
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Peter J Mariani	officer: Chief Financial Officer	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Amy Mcbride Wendell	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Burke William P. Mr.	director	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Guido J Neels	director	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Marc A Began	officer: EVP & General Counsel	C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph A. Tyndall	director	13631 PROGRESS BLVD., SUITE 400, ALACHUA FL 32615
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Maria D. Martinez	officer: Chief Human Resources Officer	C/O AXOGEN INC., 13631 PROGRESS BLVD, SUITE 400, ALACHUA FL 32615
Mark Stephen Gold	director	13859 PROGRESS BLVD SUITE 100, ALACHUA FL 32615
Paul Thomas	director	ONE MILLENNIUM WAY, BRANCHBURG NJ 08876